http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kwon Hyo Eun,Ko Nayeon,Yuk Doyoung,Choi Seo Won,Koh Seong-Eun 대한재활의학회 2023 Annals of Rehabilitation Medicine Vol.47 No.5
Objective: To systematically review the effects of protein supplementation in older adults with sarcopenia.Methods: A systematic literature search was conducted in PubMed, Cochrane Library, and Embase databases until May 2023. The inclusion criteria were as follows: (1) randomized controlled trials with a quantitative study design; (2) studies with a study group of older adults with sarcopenia; (3) studies comparing muscle mass, muscle strength, and performance of older adults with sarcopenia after protein supplementation; and (4) studies published up to May 2023.Results: Six retrospective comparative studies, including 715 patients, met the inclusion criteria. The nutritional supplementation group exhibited significant improvement in appendicular skeletal muscle mass (standardized mean difference [SMD]=0.41; 95% confidence interval [CI], 0.24–0.58; p<0.001; I<sup>2</sup>=1%), while handgrip strength (SMD=0.37; 95% CI, -0.32–1.07; p=0.29; I<sup>2</sup>=94%) and Short Physical Performance Battery (SPPB) (SMD=0.35; 95% CI, -0.47–1.18; p=0.40; I<sup>2</sup>=94%) showed a tendency for improvement.Conclusion: Nutritional supplementation with protein increased appendicular muscle mass in older adults with sarcopenia and improved handgrip strength and SPPB scores.
Choo, Eun Ho,Lee, Jun-Ho,Park, Eun-Hye,Park, Hyo Eun,Jung, Nam-Chul,Kim, Tae-Hoon,Koh, Yoon-Seok,Kim, Eunmin,Seung, Ki-Bae,Park, Cheongsoo,Hong, Kwan-Soo,Kang, Kwonyoon,Song, Jie-Young,Seo, Han Geuk,L American Heart Association, Inc. 2017 CIRCULATION - Vol.135 No.15
<P>Conclusions: This study showed that tDC therapy in a preclinical model of MI was potentially translatable into an antiremodeling therapy for ischemic tissue repair.</P>
Lee, Jeong-Eun,Seo, Inweon,Jeong, Soo-Jin,Koh, Wonil,Jung, Ji Hoon,Kwon, Tae-Rin,Lee, Hyo-Jung,Han, Ihn,Lee, Hyo-Jeong,Lee, Eun-Ok,Kim, Sun-Hyung,Jung, Hee-Jae,Lu, Junxuan,Kim, Sung-Hoon Institute for Advanced Research in Asian Science a 2011 The American journal of Chinese medicine Vol.39 No.6
<P>Ka-mi-kae-kyuk-tang (KMKKT) is an Oriental herbal medicinal cocktail. Our collaborative team has shown that it has potent anti-angiogenic, anti-cancer and anti-metastatic activities in vivo without observable side effects. We have documented evidence for KMKKT to alleviate drug-induced hematotoxicity in vivo. In the present study, we investigated the mechanistic and signaling events through which KMKKT enhances hematopoiesis, using hematopoietic stem cells (HSCs) isolated from the bone marrow of 8-12 week-old C57BL/6 mice. Our results show that KMKKT significantly increased the expression of the hematopoietic cytokines interleukin (IL)-3, stem cell factor (SCF), granulocyte-macrophage-colony stimulating factor (GM-CSF), thrombopoietin (TPO) and erythropoietin (EPO) at the level of mRNA and secretion in HSCs. KMKKT also increased the expression of c-Kit, a cytokine receptor expressed in HSCs. In addition, KMKKT enhanced phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5), and increased the binding activity of STAT5 to gamma interferon activated sites (GAS) that mediate JAK2 downstream signaling. Furthermore, we found that KMKKT significantly enhanced the growth rate of colony-forming unit granulocyte erythrocyte monocyte macrophages (CFU-GEMM) and burst forming unit erythroid (BFU-E) of mouse HSCs (mHSCs) stimulated by IL-3/EPO. Overall, our results demonstrated that KMKKT alleviated drug-induced side effects through enhanced hematopoiesis, at least in part through cytokine-mediated JAK2/STAT5 signaling.</P>
Koh, Wonil,Jeong, Soo‐,Jin,Lee, Hyo‐,Jung,Ryu, Ho‐,Geon,Lee, Eun‐,Ok,Ahn, Kyoo Seok,Bae, Hyunsu,Kim, Sung‐,Hoon Blackwell Publishing Ltd 2011 Journal of pineal research Vol.50 No.4
<P><B>Abstract: </B> Melatonin, a naturally occurring molecule, is produced by the pineal gland in a circadian manner to regulate biologic rhythms in humans. Recent studies report that melatonin may be an attractive candidate as an anticancer agent or for combined therapy because of its antioxidant, oncostatic and immunoregulatory activities. In this study, the potentiating effect of melatonin was evaluated on the apoptosis induced by puromycin as an anticancer drug in acute promyelocytic leukemia HL‐60 cells. Melatonin did not show significant cytotoxicity against HL‐60 cells compared to puromycin. However, melatonin significantly augmented the cytotoxicity of puromycin. Consistently, combined treatment of melatonin and puromycin reduced the expression of anti‐apoptotic proteins, such as bcl‐2 and bcl‐x<SUB>L</SUB>, and also induced caspase‐3 activation and poly (ADP‐ribose) polymerase (PARP) cleavage compared to puromycin treatment alone. Furthermore, cell cycle analysis revealed that melatonin promoted puromycin‐induced apoptosis by increasing the sub‐G1 population, but suppressing G2/M arrest in HL‐60 cells. Interestingly, melatonin activated the phosphorylation of 5′‐adenosine monophosphate‐activated kinase (AMPK) in combination with puromycin. Taken together, our results suggest that melatonin potentiates puromycin‐induced apoptosis with caspase‐3 and AMPK activation in HL‐60 cells, and thus, melatonin treatment can be effectively applied to leukemia treatment as a potential sensitizer for chemotherapeutic agents.</P>
Effect of Estrogen on Hepatic Ischemia and Reperfusion Injury in Rats
Eun-Hae Cho,Jin-Hee Sung,Myeong-Ok Kim,Han-Nah Jung,Chung-Kil Won,Jae-Hyun Cho,Hyo-Jong Lee,Phil-Ok Koh 한국실험동물학회 2008 Laboratory Animal Research Vol.24 No.3
It is known that estrogen protects tissues against organ ischemia. This study examined the protective effect of estrogen against hepatic ischemia and reperfusion. Rats were subjected to hepatic ischemia for 60 min and were sacrificed at 3, 6, 12, 24 hr after reperfusion. Estrogen (4 ㎎/㎏) or oil was administered at 1 hr before hepatic ischemia. Alanine aminotransferase and asparatate aminotransferase levels were immediately increased after reperfusion, peaked at 6 hr and then declined gradually. Alanine aminotransferase and asparatate aminotransferase levels were significantly suppressed by estrogen treatment. After 24 hr of reperfusion, ischemic lobe showed inflammatory lesions with severe congestion in oil-treated group. However, in estrogen-treated group, only mild congestion was observed. In histological observation, severity of hepatic injury was getting worse in process of time. In oil-treated animals, most ischemic liver lobes showed hepatocyte necrosis and massive neutrophils infiltration. However, estrogen attenuated the damage of hepatic tissue caused by hepatic ischemic and reperfusion injury. Thus, our results suggest that estrogen play a potent protective role against hepatic injury.
Estrogen Treatment Attenuates Apoptotic Cell Death Following Spinal Cord Injury in Rats
Eun-Hae Cho,Jin-Hee Sung,Myeong-Ok Kim,Wongi Min,Chung-Kil Won,Jae-Hyun Cho,Hyo-Jong Lee,Phil-Ok Koh 한국실험동물학회 2009 Laboratory Animal Research Vol.25 No.2
Estrogen exerts a neuroprotective effect by reducing apoptotic cell death in both brain injury and spinal cord injury. This study investigated whether estrogen contributes to the cleavage of poly (ADP-ribose) polymerase (PARP), an indicator of apoptotic cell death, during spinal cord injury. Adult female rats were ovariectomized and treated with oil or estrogen prior to spinal cord injury. Spinal cord tissues were collected at 24 hr after injury. Estrogen treatment showed a significant improvement of spinal cord tissue morphology and markedly reduced numbers of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells. Using Western blot analysis, we found that the level of cleaved PARP was increased in oil-treated animals, whereas estrogen prevented the injury-induced increase in PARP cleavage. The results of this study provide further evidence that estrogen inhibits apoptotic cell death through the down-regulation of cleaved PARP in spinal cord injury.
Koh, Kyung-Nam,Im, Ho Joon,Kim, Hyery,Kang, Hyoung Jin,Park, Kyung Duk,Shin, Hee Young,Ahn, Hyo Seop,Lee, Ji Won,Yoo, Keon Hee,Sung, Ki Woong,Koo, Hong Hoe,Lim, Young Tak,Park, Jun Eun,Park, Byung-Kiu KOREAN ACADEMY OF MEDICAL SCIENCE 2017 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.32 No.4
<P>This multicenter, prospective trial was conducted to develop an effective and safe reinduction regimen for marrow-relapsed pediatric acute lymphoblastic leukemia (ALL) by modifying the dose of idarubicin. Between 2006 and 2009, the trial accrued 44 patients, 1 to 21 years old with first marrow-relapsed ALL. The reinduction regimen comprised prednisolone, vincristine, L-asparaginase, and idarubicin (10 mg/m<SUP>2</SUP>/week). The idarubicin dose was adjusted according to the degree of myelosuppression. The second complete remission (CR2) rate was 72.7%, obtained by 54.2% of patients with early relapse < 24 months after initial diagnosis and 95.0% of those with late relapse (<I>P</I> = 0.002). Five patients entered remission with extended treatment, resulting in a final CR2 rate of 84.1%. The CR2 rate was not significantly different according to the idarubicin dose. The induction death rate was 2.3% (1/44). The 5-year event-free and overall survival rates were 22.2% ± 6.4% and 27.3% ± 6.7% for all patients, 4.2% ± 4.1% and 8.3% ± 5.6% for early relapsers, and 43.8% ± 11.4% and 50.0% ± 11.2% for late relapsers, respectively. Early relapse and slow response to reinduction chemotherapy were predictors of poor outcomes. In conclusion, a modified dose of idarubicin was effectively incorporated into the reinduction regimen for late marrow-relapsed ALL with a low toxic death rate. However, the CR2 rate for early relapsers was suboptimal, and the second remission was not durable in most patients.</P>